IN2015DN00820A - - Google Patents

Info

Publication number
IN2015DN00820A
IN2015DN00820A IN820DEN2015A IN2015DN00820A IN 2015DN00820 A IN2015DN00820 A IN 2015DN00820A IN 820DEN2015 A IN820DEN2015 A IN 820DEN2015A IN 2015DN00820 A IN2015DN00820 A IN 2015DN00820A
Authority
IN
India
Prior art keywords
relates
present
macular degeneration
baclofen
combinations
Prior art date
Application number
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of IN2015DN00820A publication Critical patent/IN2015DN00820A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN820DEN2015 2012-07-18 2013-07-18 IN2015DN00820A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (1)

Publication Number Publication Date
IN2015DN00820A true IN2015DN00820A (enrdf_load_html_response) 2015-06-12

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN820DEN2015 IN2015DN00820A (enrdf_load_html_response) 2012-07-18 2013-07-18

Country Status (17)

Country Link
US (1) US9545389B2 (enrdf_load_html_response)
EP (1) EP2874617B1 (enrdf_load_html_response)
JP (1) JP6271539B2 (enrdf_load_html_response)
KR (1) KR20150058159A (enrdf_load_html_response)
CN (1) CN104780917B (enrdf_load_html_response)
AU (1) AU2013291970B2 (enrdf_load_html_response)
BR (1) BR112015001090A2 (enrdf_load_html_response)
CA (1) CA2879114A1 (enrdf_load_html_response)
EA (1) EA029157B1 (enrdf_load_html_response)
ES (1) ES2729208T3 (enrdf_load_html_response)
IL (1) IL236737B (enrdf_load_html_response)
IN (1) IN2015DN00820A (enrdf_load_html_response)
MX (1) MX364232B (enrdf_load_html_response)
NZ (1) NZ704280A (enrdf_load_html_response)
SG (1) SG11201500309VA (enrdf_load_html_response)
WO (1) WO2014013025A1 (enrdf_load_html_response)
ZA (1) ZA201500663B (enrdf_load_html_response)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015063140A1 (en) 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
JP6619744B2 (ja) 2014-02-11 2019-12-11 ファーネクストPharnext 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7109239B2 (en) 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
JP4927563B2 (ja) 2003-12-30 2012-05-09 ゼノポート,インコーポレイティド アシルオキシアルキルカルバメートプロドラッグ及び中間体の合成
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2009004082A2 (en) * 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033061A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009061934A1 (en) 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
WO2010089355A1 (en) 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
EP2403486A1 (en) * 2009-03-03 2012-01-11 XenoPort, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
EP2419401A2 (en) 2009-04-17 2012-02-22 XenoPort, Inc. GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
EP2560631B1 (en) * 2011-03-01 2014-01-15 Pharnext Baclofen and acamprosate based therapy of neurogical disorders

Also Published As

Publication number Publication date
IL236737B (en) 2018-12-31
MX2015000777A (es) 2015-10-14
WO2014013025A1 (en) 2014-01-23
MX364232B (es) 2019-04-16
BR112015001090A2 (pt) 2017-06-27
EA029157B1 (ru) 2018-02-28
HK1209335A1 (en) 2016-04-01
JP6271539B2 (ja) 2018-01-31
SG11201500309VA (en) 2015-02-27
EP2874617B1 (en) 2019-02-27
JP2015522601A (ja) 2015-08-06
ZA201500663B (en) 2016-10-26
CN104780917B (zh) 2017-09-08
US20150238452A1 (en) 2015-08-27
EP2874617A1 (en) 2015-05-27
ES2729208T3 (es) 2019-10-30
EA201500143A1 (ru) 2015-05-29
KR20150058159A (ko) 2015-05-28
AU2013291970B2 (en) 2017-09-28
NZ704280A (en) 2017-06-30
AU2013291970A1 (en) 2015-02-19
CN104780917A (zh) 2015-07-15
IL236737A0 (en) 2015-02-26
CA2879114A1 (en) 2014-01-23
US9545389B2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
IN2014DN00288A (enrdf_load_html_response)
IN2014DN00286A (enrdf_load_html_response)
IN2014MN00093A (enrdf_load_html_response)
IN2014MN01378A (enrdf_load_html_response)
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
IN2014DN06792A (enrdf_load_html_response)
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
PH12015500525A1 (en) Formulations of enzalutamide
NZ720949A (en) Methods and compositions for treating aging-associated conditions
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2013061161A3 (en) New combination therapies for treating neurological disorders
MX348495B (es) Metodos y composiciones para el control de malezas.
IN2014DN05885A (enrdf_load_html_response)
GB201210699D0 (en) Nutritional food
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
MX2014014443A (es) Agentes de ligacion a tlr3.
IN2015DN00820A (enrdf_load_html_response)
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
MX2017004986A (es) Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2 para terapias oculares.
WO2012166659A3 (en) Anti-emr1 antibodies
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
WO2013101509A3 (en) Hsp70 fusion protein conjugates and uses thereof